JP2008533151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533151A5 JP2008533151A5 JP2008501948A JP2008501948A JP2008533151A5 JP 2008533151 A5 JP2008533151 A5 JP 2008533151A5 JP 2008501948 A JP2008501948 A JP 2008501948A JP 2008501948 A JP2008501948 A JP 2008501948A JP 2008533151 A5 JP2008533151 A5 JP 2008533151A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- amide
- benzimidazole
- imidazol
- benzimidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- -1 {4- [2- (1H- benzimidazol-2-yl) - ethylcarbamoyl]-1H-benzimidazol-2-yl} - amide Chemical compound 0.000 claims 4
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 3
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 2
- 206010012239 Delusion Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 231100000868 delusion Toxicity 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000007406 plaque accumulation Effects 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- REDRQHKMLWLDKF-UHFFFAOYSA-N 2-(isoquinolin-3-ylamino)-n-(4-methoxyphenyl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CC=CC2=C1NC(NC=1N=CC3=CC=CC=C3C=1)=N2 REDRQHKMLWLDKF-UHFFFAOYSA-N 0.000 claims 1
- DPZXAHOQZNGFFO-UHFFFAOYSA-N 2-(isoquinolin-3-ylamino)-n-phenyl-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2N=C(NC=3N=CC4=CC=CC=C4C=3)NC=2C=1C(=O)NC1=CC=CC=C1 DPZXAHOQZNGFFO-UHFFFAOYSA-N 0.000 claims 1
- BXQYWBDHNSYVRY-UHFFFAOYSA-N 2-[(1,5-dimethylindole-2-carbonyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC(C)=CC=C2N(C)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 BXQYWBDHNSYVRY-UHFFFAOYSA-N 0.000 claims 1
- UFJMFVZQYLOJFB-UHFFFAOYSA-N 2-[(1-benzylindole-2-carbonyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2N(CC=2C=CC=CC=2)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 UFJMFVZQYLOJFB-UHFFFAOYSA-N 0.000 claims 1
- BTFKPFGRLMNQNW-UHFFFAOYSA-N 2-[(2-chlorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 BTFKPFGRLMNQNW-UHFFFAOYSA-N 0.000 claims 1
- XNXBQZHJNSDVQM-UHFFFAOYSA-N 2-[(2-fluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound FC1=CC=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 XNXBQZHJNSDVQM-UHFFFAOYSA-N 0.000 claims 1
- PUFIGMFPXPZODO-UHFFFAOYSA-N 2-[(3,4-dimethoxybenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 PUFIGMFPXPZODO-UHFFFAOYSA-N 0.000 claims 1
- YYCWDBDINNAQTH-UHFFFAOYSA-N 2-[(3,5-difluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound FC1=CC(F)=CC(C(=O)NC=2NC3=C(C(=O)NC=4NC=CN=4)C=CC=C3N=2)=C1 YYCWDBDINNAQTH-UHFFFAOYSA-N 0.000 claims 1
- YQZGCJOCTVTNGB-UHFFFAOYSA-N 2-[(3-fluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound FC1=CC=CC(C(=O)NC=2NC3=C(C(=O)NC=4NC=CN=4)C=CC=C3N=2)=C1 YQZGCJOCTVTNGB-UHFFFAOYSA-N 0.000 claims 1
- QBRTUDWKEZRWNB-UHFFFAOYSA-N 2-[(4-chlorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1C(=O)NC1=NC2=C(C(=O)NC=3NC=CN=3)C=CC=C2N1 QBRTUDWKEZRWNB-UHFFFAOYSA-N 0.000 claims 1
- UEGPDKFYZHJHSK-UHFFFAOYSA-N 2-[(4-fluoro-3-methoxybenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=C(F)C(OC)=CC(C(=O)NC=2NC3=C(C(=O)NC=4NC=CN=4)C=CC=C3N=2)=C1 UEGPDKFYZHJHSK-UHFFFAOYSA-N 0.000 claims 1
- NRBIGPPBQPOAIW-UHFFFAOYSA-N 2-[(4-fluorobenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 NRBIGPPBQPOAIW-UHFFFAOYSA-N 0.000 claims 1
- MKUUBNAKDGUWGG-UHFFFAOYSA-N 2-[(4-tert-butylbenzoyl)amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 MKUUBNAKDGUWGG-UHFFFAOYSA-N 0.000 claims 1
- BONUWFJMAMKJBS-UHFFFAOYSA-N 2-[[2-(4-fluorophenyl)acetyl]amino]-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 BONUWFJMAMKJBS-UHFFFAOYSA-N 0.000 claims 1
- FLXAMFSUBWKOGC-UHFFFAOYSA-N 2-amino-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=12NC(N)=NC2=CC=CC=1C(=O)NC1=NC=CN1 FLXAMFSUBWKOGC-UHFFFAOYSA-N 0.000 claims 1
- SIOYHWABOSESEJ-UHFFFAOYSA-N 2-benzamido-n-(1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 SIOYHWABOSESEJ-UHFFFAOYSA-N 0.000 claims 1
- RJBYQNGSOBFWIL-UHFFFAOYSA-N 2-isoquinolin-3-yl-n-(5-phenyl-1h-imidazol-2-yl)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2NC(C=3N=CC4=CC=CC=C4C=3)=NC=2C=1C(=O)NC(NC=1)=NC=1C1=CC=CC=C1 RJBYQNGSOBFWIL-UHFFFAOYSA-N 0.000 claims 1
- MIPKQHRPGRGBIU-UHFFFAOYSA-N 6,7-dimethoxyisoquinoline-3-carboxylic acid Chemical compound N1=C(C(O)=O)C=C2C=C(OC)C(OC)=CC2=C1 MIPKQHRPGRGBIU-UHFFFAOYSA-N 0.000 claims 1
- 229940124810 Alzheimer's drug Drugs 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000007131 anti Alzheimer effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- AOOXGPCQXPZOMB-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(1h-indole-2-carbonylamino)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC=C2NC(C(NC=3NC4=CC=CC(=C4N=3)C(=O)NC=3NC4=CC=CC=C4N=3)=O)=CC2=C1 AOOXGPCQXPZOMB-UHFFFAOYSA-N 0.000 claims 1
- KMDDVYGNFWMWCX-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-(pyridin-2-ylamino)-3h-benzimidazole-5-carboxamide Chemical compound N=1C2=CC=CC=C2NC=1NC(=O)C(C=C1N2)=CC=C1N=C2NC1=CC=CC=N1 KMDDVYGNFWMWCX-UHFFFAOYSA-N 0.000 claims 1
- KNAXPDGBZIEBTP-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-naphthalen-2-yl-3h-benzimidazole-5-carboxamide Chemical compound C1=CC=CC2=CC(C=3NC4=CC=C(C=C4N=3)C(NC=3NC4=CC=CC=C4N=3)=O)=CC=C21 KNAXPDGBZIEBTP-UHFFFAOYSA-N 0.000 claims 1
- UKVNFJNGGMOKPQ-UHFFFAOYSA-N n-(1h-benzimidazol-2-yl)-2-pyridin-2-yl-3h-benzimidazole-5-carboxamide Chemical compound N=1C2=CC=CC=C2NC=1NC(=O)C(C=C1N=2)=CC=C1NC=2C1=CC=CC=N1 UKVNFJNGGMOKPQ-UHFFFAOYSA-N 0.000 claims 1
- UTXQATYHCDTLPU-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(1h-indole-2-carbonylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2NC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 UTXQATYHCDTLPU-UHFFFAOYSA-N 0.000 claims 1
- BCQWSULEBBKAMJ-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2N=C(NC=3N=CC4=CC=CC=C4C=3)NC=2C=1C(=O)NC1=NC=CN1 BCQWSULEBBKAMJ-UHFFFAOYSA-N 0.000 claims 1
- GDDDHZOHBVARSC-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(isoquinolin-3-ylamino)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2N=C(NC=3N=CC4=CC=CC=C4C=3)NC2=CC=1C(=O)NC1=NC=CN1 GDDDHZOHBVARSC-UHFFFAOYSA-N 0.000 claims 1
- ADHBNWAYMZEQSF-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(naphthalene-2-carbonylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 ADHBNWAYMZEQSF-UHFFFAOYSA-N 0.000 claims 1
- LLEMLFSSJSZFOR-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-(pyridin-2-ylamino)-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2N=C(NC=3N=CC=CC=3)NC2=CC=1C(=O)NC1=NC=CN1 LLEMLFSSJSZFOR-UHFFFAOYSA-N 0.000 claims 1
- IROXPLUVFLJDGO-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(1-methylindole-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2N(C)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 IROXPLUVFLJDGO-UHFFFAOYSA-N 0.000 claims 1
- HWFCVPBQVAHWNK-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(1-propylindole-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC=CC=C2N(CCC)C=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 HWFCVPBQVAHWNK-UHFFFAOYSA-N 0.000 claims 1
- FDISPZPLEREWPS-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-methoxybenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 FDISPZPLEREWPS-UHFFFAOYSA-N 0.000 claims 1
- FKWFBUSCPMWNPI-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-nitrobenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 FKWFBUSCPMWNPI-UHFFFAOYSA-N 0.000 claims 1
- BZAYJTGSTUVJPM-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-phenoxybenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 BZAYJTGSTUVJPM-UHFFFAOYSA-N 0.000 claims 1
- NQFWEZBPLUCTPE-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-phenylbenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 NQFWEZBPLUCTPE-UHFFFAOYSA-N 0.000 claims 1
- NCUWSQJNQBFGQM-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(4-propan-2-ylbenzoyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1C(=O)NC1=NC2=CC=CC(C(=O)NC=3NC=CN=3)=C2N1 NCUWSQJNQBFGQM-UHFFFAOYSA-N 0.000 claims 1
- RPUAYSHJAPTPRI-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(5-methyl-1h-indole-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C2=CC(C)=CC=C2NC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 RPUAYSHJAPTPRI-UHFFFAOYSA-N 0.000 claims 1
- YPUOEDZEMODXLR-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[(6-phenoxypyridine-2-carbonyl)amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC(OC=2C=CC=CC=2)=NC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 YPUOEDZEMODXLR-UHFFFAOYSA-N 0.000 claims 1
- HFHWSAODUBTRNO-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[[4-(trifluoromethyl)benzoyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)NC1=NC2=C(C(=O)NC=3NC=CN=3)C=CC=C2N1 HFHWSAODUBTRNO-UHFFFAOYSA-N 0.000 claims 1
- UYKBRBDEUIHXGH-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[[5-(2-phenylethynyl)pyridine-3-carbonyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1N=CC(C#CC=2C=CC=CC=2)=CC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 UYKBRBDEUIHXGH-UHFFFAOYSA-N 0.000 claims 1
- BNCARJAWLUNMPH-UHFFFAOYSA-N n-(1h-imidazol-2-yl)-2-[[6-(2-phenylethynyl)pyridine-2-carbonyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC(C#CC=2C=CC=CC=2)=NC=1C(=O)NC(NC1=CC=C2)=NC1=C2C(=O)NC1=NC=CN1 BNCARJAWLUNMPH-UHFFFAOYSA-N 0.000 claims 1
- VCMBSXHBEUBPMZ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1=CC=CC2=C1NC(NC=1N=CC3=CC=CC=C3C=1)=N2 VCMBSXHBEUBPMZ-UHFFFAOYSA-N 0.000 claims 1
- YEGCIUAOIVAIKE-UHFFFAOYSA-N n-(4-fluorophenyl)-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=CC2=C1NC(NC=1N=CC3=CC=CC=C3C=1)=N2 YEGCIUAOIVAIKE-UHFFFAOYSA-N 0.000 claims 1
- OIEBPWKAVOFYAU-UHFFFAOYSA-N n-[4-(1h-benzimidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C1=CC=C2C=NC(C(NC=3NC4=C(C(=O)NC=5NC6=CC=CC=C6N=5)C=CC=C4N=3)=O)=CC2=C1 OIEBPWKAVOFYAU-UHFFFAOYSA-N 0.000 claims 1
- YTIHWBQYPRIIBE-UHFFFAOYSA-N n-[4-(1h-imidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=1C2=CC=CC=C2C=NC=1C(=O)NC(NC1=2)=NC1=CC=CC=2C(=O)NC1=NC=CN1 YTIHWBQYPRIIBE-UHFFFAOYSA-N 0.000 claims 1
- AVBAIVJQGVVFMH-UHFFFAOYSA-N n-[4-(1h-imidazol-2-ylcarbamoyl)-6-(3-methylbutanoylamino)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=12N=C(NC(=O)C=3N=CC4=CC=CC=C4C=3)NC2=CC(NC(=O)CC(C)C)=CC=1C(=O)NC1=NC=CN1 AVBAIVJQGVVFMH-UHFFFAOYSA-N 0.000 claims 1
- BMZUPQXUWTYOGL-UHFFFAOYSA-N n-[4-(1h-imidazol-2-ylcarbamoyl)-6-[(2-phenylacetyl)amino]-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=1C(C(=O)NC=2NC=CN=2)=C2NC(NC(=O)C=3N=CC4=CC=CC=C4C=3)=NC2=CC=1NC(=O)CC1=CC=CC=C1 BMZUPQXUWTYOGL-UHFFFAOYSA-N 0.000 claims 1
- DHLGALGXGWELNN-UHFFFAOYSA-N n-[6-(1h-benzimidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C1=CC=C2C=NC(C(=O)NC=3NC4=CC=C(C=C4N=3)C(NC=3NC4=CC=CC=C4N=3)=O)=CC2=C1 DHLGALGXGWELNN-UHFFFAOYSA-N 0.000 claims 1
- MDXUDGLOFAJZRO-UHFFFAOYSA-N n-[6-benzamido-4-(1h-imidazol-2-ylcarbamoyl)-1h-benzimidazol-2-yl]isoquinoline-3-carboxamide Chemical compound C=1C=CC=CC=1C(=O)NC(C=C1NC(NC(=O)C=2N=CC3=CC=CC=C3C=2)=NC1=1)=CC=1C(=O)NC1=NC=CN1 MDXUDGLOFAJZRO-UHFFFAOYSA-N 0.000 claims 1
- JWMDMOYMTPPOQC-UHFFFAOYSA-N n-benzyl-2-(isoquinolin-3-ylamino)-1h-benzimidazole-4-carboxamide Chemical compound C=1C=CC=2N=C(NC=3N=CC4=CC=CC=C4C=3)NC=2C=1C(=O)NCC1=CC=CC=C1 JWMDMOYMTPPOQC-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66134905P | 2005-03-14 | 2005-03-14 | |
| US60/661,349 | 2005-03-14 | ||
| PCT/US2006/009049 WO2006099379A2 (en) | 2005-03-14 | 2006-03-14 | Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011256487A Division JP2012046541A (ja) | 2005-03-14 | 2011-11-24 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008533151A JP2008533151A (ja) | 2008-08-21 |
| JP2008533151A5 true JP2008533151A5 (https=) | 2011-02-03 |
| JP5066514B2 JP5066514B2 (ja) | 2012-11-07 |
Family
ID=36694148
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501948A Expired - Fee Related JP5066514B2 (ja) | 2005-03-14 | 2006-03-14 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
| JP2011256487A Ceased JP2012046541A (ja) | 2005-03-14 | 2011-11-24 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011256487A Ceased JP2012046541A (ja) | 2005-03-14 | 2011-11-24 | ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20060223849A1 (https=) |
| EP (2) | EP1863771B1 (https=) |
| JP (2) | JP5066514B2 (https=) |
| CN (1) | CN101142194B (https=) |
| AU (1) | AU2006223070B2 (https=) |
| BR (1) | BRPI0608581A2 (https=) |
| CA (1) | CA2600570C (https=) |
| ES (1) | ES2400287T3 (https=) |
| IL (2) | IL185541A (https=) |
| MX (1) | MX2007011234A (https=) |
| NZ (1) | NZ561029A (https=) |
| WO (1) | WO2006099379A2 (https=) |
| ZA (2) | ZA200707896B (https=) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| CN101379060B (zh) * | 2006-02-10 | 2012-05-23 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| CA2641880C (en) | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| EP2010520B1 (en) * | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| US20100056515A1 (en) * | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
| JP2010514672A (ja) | 2006-12-29 | 2010-05-06 | 武田薬品工業株式会社 | Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物 |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| JP5383484B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | 環式基で置換されたアミノジヒドロチアジン誘導体 |
| CA2685266C (en) * | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| CA2685540C (en) * | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| NZ585298A (en) | 2007-11-16 | 2012-08-31 | Rigel Pharmaceuticals Inc | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| EP2231666B1 (en) | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| FR2925904B1 (fr) * | 2008-01-02 | 2010-01-01 | Sanofi Aventis | DERIVES DE N-HETEROCYCLIQUE-6-HETEROCYCLIQUE-IMIDAZO°1,2-a! PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| BRPI0911681B8 (pt) | 2008-04-23 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro |
| DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| CA2725481A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| CA2729128C (en) * | 2008-07-03 | 2016-05-31 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
| JP5693452B2 (ja) * | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
| US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| US8394969B2 (en) | 2008-09-26 | 2013-03-12 | Merck Sharp & Dohme Corp. | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| EP2352374B1 (en) | 2008-10-29 | 2014-09-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
| CN101619058A (zh) * | 2009-01-08 | 2010-01-06 | 上海交通大学 | 一种苯并咪唑-4-酰胺型衍生物 |
| US20100278835A1 (en) * | 2009-03-10 | 2010-11-04 | Astrazeneca Uk Limited | Novel compounds 660 |
| MX2011010218A (es) | 2009-04-02 | 2011-10-10 | Merck Patent Gmbh | Inhibidores de autotaxina. |
| JP2012525389A (ja) * | 2009-04-27 | 2012-10-22 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 置換イソキノリン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法 |
| AU2010241929A1 (en) * | 2009-04-27 | 2011-10-06 | High Point Pharmaceuticals, Llc | Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors |
| SG176009A1 (en) * | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| AU2010287976A1 (en) * | 2009-08-31 | 2012-03-29 | Ihara Chemical Industry Co., Ltd. | Process for preparation of pyrimidinylacetonitrile derivatives and intermediates for synthesis thereof |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| MX2012006491A (es) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
| WO2011074658A1 (ja) | 2009-12-18 | 2011-06-23 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
| EP2523949B1 (en) | 2010-01-15 | 2014-08-20 | Janssen Pharmaceuticals Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| CA2787365A1 (en) | 2010-01-25 | 2011-07-28 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| EP2549874A4 (en) * | 2010-03-23 | 2013-10-02 | High Point Pharmaceuticals Llc | SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| EP2643299B1 (en) | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| TWI567079B (zh) | 2011-07-15 | 2017-01-21 | 健生醫藥公司 | 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物 |
| PH12014500326B1 (en) | 2011-08-18 | 2018-01-10 | Nippon Shinyaku Co Ltd | Heterocyclic derivative and pharmaceutical drug |
| KR20140072037A (ko) | 2011-08-30 | 2014-06-12 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법 |
| SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| EP3366685A1 (en) * | 2012-01-09 | 2018-08-29 | X-Chem, Inc. | Tryptoline derivatives having kinase inhibitory activity and uses thereof |
| WO2013104577A1 (en) | 2012-01-11 | 2013-07-18 | Acesion Pharma Aps | Benzimidazolyl-acetamide derivatives useful as potassium channel modulators |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| NZ702611A (en) | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| CN103772376B (zh) * | 2012-10-24 | 2017-01-11 | 中国医学科学院医药生物技术研究所 | 取代的苯并-1,3-杂唑类化合物、其制备方法及用途 |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| AU2013366668B2 (en) | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| ES2612215T3 (es) | 2013-01-17 | 2017-05-12 | Janssen Pharmaceutica, N.V. | Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa |
| US9475806B2 (en) | 2013-03-14 | 2016-10-25 | Novartis Ag | Complement factor B inhibitors and uses there of |
| SI3010503T1 (sl) * | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
| JP6542212B2 (ja) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメイン阻害剤としての新規キナゾリノン |
| CN105849090A (zh) | 2013-10-30 | 2016-08-10 | 诺华股份有限公司 | 2-苄基-苯并咪唑补体因子b抑制剂及其用途 |
| AU2014353150A1 (en) | 2013-11-19 | 2016-07-07 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5 |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| EA031655B1 (ru) | 2014-02-11 | 2019-02-28 | Байер Фарма Акциенгезельшафт | Бензимидазол-2-амины в качестве ингибиторов midhi |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| AU2015289492B2 (en) | 2014-07-17 | 2020-02-20 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| WO2016062677A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| JP6672288B2 (ja) | 2014-10-23 | 2020-03-25 | バイエル・ファルマ・アクティエンゲゼルシャフト | 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| EP3303302B1 (en) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| JP6824954B2 (ja) | 2015-07-16 | 2021-02-03 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール |
| BR112018003812B1 (pt) * | 2015-09-18 | 2024-04-30 | Merck Patent Gmbh | Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit |
| CN108602776B (zh) * | 2015-09-18 | 2021-12-03 | 默克专利有限公司 | 用作irak抑制剂的杂芳基化合物及其用途 |
| AU2016371598B2 (en) * | 2015-12-15 | 2021-05-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| GB201619694D0 (en) * | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| CN106986809B (zh) * | 2016-12-02 | 2020-03-24 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种5-溴-6-氯-3-吲哚辛酯的合成方法 |
| TWI791593B (zh) * | 2017-08-21 | 2023-02-11 | 德商馬克專利公司 | 做為腺苷受體拮抗劑之苯并咪唑衍生物 |
| JP7313364B2 (ja) * | 2018-02-21 | 2023-07-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体 |
| CN109400528B (zh) * | 2018-12-18 | 2022-03-15 | 深圳科兴药业有限公司 | 一种可博美的合成方法 |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| US12227475B2 (en) * | 2021-04-27 | 2025-02-18 | X-Biotix Therapeutics, Inc. | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions |
| US20240300939A1 (en) | 2021-06-14 | 2024-09-12 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| CN113387959B (zh) * | 2021-06-24 | 2023-05-05 | 烟台理工学院 | 一种噻吩并[3,2-c]吡啶-6-羧酸甲酯的合成方法 |
| WO2024211836A2 (en) | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Semi-saturated bicyclic derivatives and related uses |
| AU2024254066A1 (en) * | 2023-04-05 | 2025-10-16 | Moma Therapeutics, Inc. | Biaryl derivatives and related uses |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401173A (en) * | 1966-04-05 | 1968-09-10 | Smith Kline French Lab | Heterocyclic acylaminobenzimidazoles |
| US3336191A (en) * | 1966-03-11 | 1967-08-15 | Smith Kline French Lab | Anthelmintic 2-amidobenzimidazoles |
| GB1122957A (en) | 1965-06-07 | 1968-08-07 | Smith Kline French Lab | Substituted benzimidazoles and anthelmintic compositions containing them |
| US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US6329163B1 (en) * | 1995-06-07 | 2001-12-11 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase inhibition |
| GB9600142D0 (en) * | 1996-01-05 | 1996-03-06 | Wellcome Found | Chemical compounds |
| JP4373497B2 (ja) * | 1996-06-19 | 2009-11-25 | ローン−プーラン・ロレ・リミテツド | 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用 |
| ES2200163T3 (es) * | 1996-11-15 | 2004-03-01 | Darwin Discovery Limited | Aril-carboxamidas biciclicas y su utilizacion terapeutica. |
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| ATE315394T1 (de) * | 1997-11-10 | 2006-02-15 | Bristol Myers Squibb Co | Benzothiazole als protein tyrosin-kinase inhibitoren |
| US6699671B1 (en) * | 1998-09-24 | 2004-03-02 | Pharmacia & Upjohn Company | Alzheimer's disease secretase, APP substrates therefor, and uses therefor |
| US20040234976A1 (en) * | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| PL205294B1 (pl) * | 1998-09-24 | 2010-03-31 | Upjohn Co | Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta |
| US6245884B1 (en) * | 1998-10-16 | 2001-06-12 | Vivian Y. H. Hook | Secretases related to alzheimer's dementia |
| TR200101498T2 (tr) * | 1998-11-27 | 2001-11-21 | Basf Aktiengesellschaft | İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları |
| GB2364059B (en) * | 1999-02-10 | 2004-01-14 | Elan Pharm Inc | Beta-Secretase enzyme compositions and methods |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| DK1194425T3 (da) * | 1999-06-23 | 2005-11-21 | Aventis Pharma Gmbh | Substituerede benzimidazoler |
| CA2374610A1 (en) * | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| SI1196408T1 (en) * | 1999-06-28 | 2005-02-28 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| CA2384378C (en) | 1999-10-06 | 2011-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| US20030092003A1 (en) * | 1999-12-29 | 2003-05-15 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of Alzheimer's disease |
| US20030143708A1 (en) * | 1999-12-29 | 2003-07-31 | Blatt La Wrence | Method and reagent for the treatment of alzheimer's disease |
| DE60124080T2 (de) * | 2000-03-23 | 2007-03-01 | Elan Pharmaceuticals, Inc., San Francisco | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit |
| CA2407088A1 (en) * | 2000-05-19 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Beta-secretase inhibitors |
| US6713276B2 (en) * | 2000-06-28 | 2004-03-30 | Scios, Inc. | Modulation of Aβ levels by β-secretase BACE2 |
| US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| CA2410898A1 (en) * | 2000-07-19 | 2002-01-24 | Pharmacia & Upjohn Company | Substrates and assays for .beta.-secretase activity |
| WO2002014319A2 (en) | 2000-08-11 | 2002-02-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| WO2002025276A1 (en) * | 2000-09-22 | 2002-03-28 | Wyeth | Crystal structure of bace and uses thereof |
| US20020157122A1 (en) * | 2000-10-27 | 2002-10-24 | Wong Philip C. | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
| JP2004517892A (ja) * | 2000-12-13 | 2004-06-17 | ワイス | β−アミロイド産生の複素環スルホンアミド阻害剤 |
| GB0101313D0 (en) * | 2001-01-18 | 2001-02-28 | Glaxo Group Ltd | Assay |
| WO2002076926A1 (en) * | 2001-02-02 | 2002-10-03 | Schering Corporation | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
| EP1233021A3 (en) * | 2001-02-20 | 2002-11-20 | Pfizer Products Inc. | An inhibitor of Beta amyloid cleavage enzyme |
| JP2004524843A (ja) * | 2001-02-23 | 2004-08-19 | イーラン ファーマスーティカルズ、インコーポレイテッド | Ｂａｃｅ−１のトランスジェニックノックアウト |
| CN1235583C (zh) | 2001-03-05 | 2006-01-11 | 特兰斯泰克制药公司 | 用作治疗剂的苯并咪唑衍生物 |
| JP2004532826A (ja) * | 2001-03-19 | 2004-10-28 | スローン−ケッタリング インスティトゥート フォー カンサー リサーチ | （ｓ，ｒ，ｒ）−（−）−アクチノニンおよびそのアナログの不斉合成、ならびにそれらの使用 |
| US20040097547A1 (en) * | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| EP1389194A2 (en) * | 2001-04-27 | 2004-02-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| FR2824825B1 (fr) * | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6562783B2 (en) * | 2001-05-30 | 2003-05-13 | Neurologic, Inc. | Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors |
| CA2451664A1 (en) * | 2001-06-25 | 2003-01-03 | Elan Pharmaceuticals, Inc. | Use of bicyclo compounds for treating alzheimer's disease |
| US20030093356A1 (en) * | 2001-07-06 | 2003-05-15 | Assetsight, Inc. | Method for issuing a derivative contract |
| MXPA04000328A (es) * | 2001-07-10 | 2004-07-23 | Pharmacia & Upjohn Comapny | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. |
| US20030109559A1 (en) * | 2001-07-11 | 2003-06-12 | Andrea Gailunas | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds |
| CA2483959A1 (en) * | 2001-08-28 | 2003-03-13 | Elan Pharmaceuticals, Inc. | Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| GB0123379D0 (en) * | 2001-09-28 | 2001-11-21 | Lorantis Ltd | Modulators |
| US7132438B2 (en) * | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| ATE369854T1 (de) * | 2001-10-19 | 2007-09-15 | Ortho Mcneil Pharm Inc | 2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs |
| WO2003037860A2 (en) * | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| AU2002359376B2 (en) * | 2001-11-08 | 2008-01-10 | Elan Pharmaceuticals, Inc. | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| JP2005509003A (ja) * | 2001-11-09 | 2005-04-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物 |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
| FR2833948B1 (fr) | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| US7273743B2 (en) * | 2002-02-21 | 2007-09-25 | Elan Pharmaceuticals, Inc. | Modified BACE |
| DE60325519D1 (de) * | 2002-03-01 | 2009-02-12 | Hoffmann La Roche | Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit |
| DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| US20040014194A1 (en) * | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| CA2484261A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| US7049333B2 (en) * | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
| EP1572129A4 (en) * | 2002-06-07 | 2007-03-28 | Univ North Carolina | AMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSE |
| PL374191A1 (en) | 2002-06-13 | 2005-10-03 | Vertex Pharmaceuticals Incorporated | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections |
| US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| US7115652B2 (en) * | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| EP1388341A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| US7338956B2 (en) * | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1539754A4 (en) * | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOCHINOLINONE AND ITS USE |
| CA2497979A1 (en) * | 2002-09-06 | 2004-03-18 | Elan Pharmaceuticals, Inc. | 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| AU2003275225A1 (en) * | 2002-09-20 | 2004-04-08 | Genelabs Technologies, Inc. | Novel aromatic compounds possessing antifungal or antibacterial activity |
| CA2507484A1 (en) * | 2002-11-27 | 2004-06-17 | Elan Pharmaceuticals, Inc. | Substituted ureas and carbamates |
| WO2004084830A2 (en) * | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
| WO2005070420A1 (en) * | 2004-01-14 | 2005-08-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| US20060223849A1 (en) * | 2005-03-14 | 2006-10-05 | Mjalli Adnan M | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| CN101379060B (zh) * | 2006-02-10 | 2012-05-23 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
-
2006
- 2006-03-14 US US11/374,723 patent/US20060223849A1/en not_active Abandoned
- 2006-03-14 US US11/885,096 patent/US7893267B2/en not_active Expired - Fee Related
- 2006-03-14 CN CN2006800084176A patent/CN101142194B/zh not_active Expired - Fee Related
- 2006-03-14 EP EP06738139A patent/EP1863771B1/en not_active Expired - Lifetime
- 2006-03-14 AU AU2006223070A patent/AU2006223070B2/en not_active Ceased
- 2006-03-14 CA CA2600570A patent/CA2600570C/en not_active Expired - Fee Related
- 2006-03-14 BR BRPI0608581-4A patent/BRPI0608581A2/pt not_active IP Right Cessation
- 2006-03-14 WO PCT/US2006/009049 patent/WO2006099379A2/en not_active Ceased
- 2006-03-14 EP EP12150487A patent/EP2457901A1/en not_active Withdrawn
- 2006-03-14 JP JP2008501948A patent/JP5066514B2/ja not_active Expired - Fee Related
- 2006-03-14 ZA ZA200707896A patent/ZA200707896B/xx unknown
- 2006-03-14 MX MX2007011234A patent/MX2007011234A/es active IP Right Grant
- 2006-03-14 ES ES06738139T patent/ES2400287T3/es not_active Expired - Lifetime
- 2006-03-14 NZ NZ561029A patent/NZ561029A/en not_active IP Right Cessation
-
2007
- 2007-08-27 IL IL185541A patent/IL185541A/en not_active IP Right Cessation
-
2009
- 2009-05-13 ZA ZA2009/03300A patent/ZA200903300B/en unknown
-
2010
- 2010-11-19 US US12/950,718 patent/US8598353B2/en not_active Expired - Fee Related
-
2011
- 2011-11-24 JP JP2011256487A patent/JP2012046541A/ja not_active Ceased
-
2012
- 2012-10-25 IL IL222698A patent/IL222698A0/en unknown
-
2013
- 2013-10-28 US US14/064,737 patent/US8946259B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533151A5 (https=) | ||
| CN105492439B (zh) | 作为溴结构域抑制剂的取代的双环化合物 | |
| CA2600570A1 (en) | Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors | |
| JP6436205B2 (ja) | キノリン誘導体 | |
| JP6708130B2 (ja) | キノリン誘導体 | |
| AU2026200630A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| RU2375046C2 (ru) | Твердый состав с улучшенными растворимостью и стабильностью и способ его получения | |
| JP2008524246A5 (https=) | ||
| JP2009521399A5 (https=) | ||
| ZA200302918B (en) | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders. | |
| HRP20161116T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI DJELUJU KAO AGONISTI β2 ADRENERGIČKOG RECEPTORA I ANTAGONISTI MUSKARINSKOG ACETILKOLINSKOG RECEPTORA M3 | |
| JP2007513915A5 (https=) | ||
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| JP2011500638A5 (https=) | ||
| AU2007329480A1 (en) | Indazole compounds | |
| JP2013523792A (ja) | Ｐｄｅ４阻害剤及びｅｐ４受容体アンタゴニストを含有する医薬の組み合わせ | |
| HRP20140593T1 (hr) | Derivati 1,3-disupstituiranih imidazolidin-2-ona kao cyp 17-inhibitori | |
| HUP0303460A2 (hu) | IgE-Módosító és sejtburjánzásgátló hatású benzimidazolok és ezeket tartalmazó gyógyszerkészítmények | |
| KR20140117684A (ko) | 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물 | |
| JP2020531454A5 (https=) | ||
| TW201900637A (zh) | N-取代吲哚衍生物 | |
| CN104023715A (zh) | 激酶抑制剂的副作用降低剂 | |
| RU2005136383A (ru) | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов | |
| JP2025519119A (ja) | Ｍｅｋ阻害剤及びその使用 | |
| CA2730225A1 (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |